AprilBio Decides 141.8 Billion Won Third-Party Allotment for R&D Funding, Dilution of 17.5% and Change in Control

AprilBio's board resolved on June 24, 2026 to conduct a 141.8 billion won third-party allotment rights offering.
The issuance of 4,095,456 new shares at 34,620 won each results in a 17.5% dilution from current outstanding shares.
All proceeds will be used for research and development expenses, and the allottees are IMM Asset Management and IMM Scale-Up Bio No. 1 LLC subject to a one-year lock-up.
Upon completion, the largest shareholder will change to IMM Asset Management, with plans to transfer the position to a special purpose company via an institutional private equity fund.
[AI Summary]This rights offering negatively impacts existing shareholders due to high dilution, but the use of funds for R&D and the participation of National Pension Service as an ultimate investor provide credibility. The overall score of 5 reflects a neutral impact.